Tumor microenvironment-targeted poly-L-glutamic acid-based combination conjugate for enhanced triple negative breast cancer treatment

Fecha de publicación:

Autores de CIPF

Participantes ajenos a CIPF

  • Balzano-Nogueira L
  • Huertas-López F

Grupos de Investigación

Abstract

The intrinsic characteristics of the tumor microenvironment (TME), including acidic pH and overexpression of hydrolytic enzymes, offer an exciting opportunity for the rational design of TME-drug delivery systems (DDS). We developed and characterized a pH-responsive biodegradable poly-L-glutamic acid (PGA)-based combination conjugate family with the aim of optimizing anticancer effects. We obtained combination conjugates bearing Doxorubicin (Dox) and aminoglutethimide (AGM) with two Dox loadings and two different hydrazone pH sensitive linkers that promote the specific release of Dox from the polymeric backbone within the TME. Low Dox loading coupled with a short hydrazone linker yielded optimal effects on primary tumor growth, lung metastasis (-90% reduction), and toxicological profile in a preclinical metastatic triple-negative breast cancer (TNBC) murine model. The use of transcriptomic analysis helped us to identify the molecular mechanisms responsible for such results including a differential immunomodulation and cell death pathways among the conjugates. This data highlights the advantages of targeting the TME, the therapeutic value of polymer-based combination approaches, and the utility of -omits-based analysis to accelerate anticancer DDS.

Datos de la publicación

ISSN/ISSNe:
0142-9612, 1878-5905

BIOMATERIALS  ELSEVIER SCI LTD

Tipo:
Article
Páginas:
8-21
PubMed:
30278346

Citas Recibidas en Web of Science: 60

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Polymer therapeutics; Polypeptides; Tumor microenvironment; Polymer-based combination conjugates; Metastatic triple-negative breast cancer; Transcriptomics

Proyectos asociados

Towards the design of Personalised Polymer-based Combiantion Nanomedicines for Advanced Stage Breast Cancer Patients

Investigador Principal: MARIA JESUS VICENT DOCON

COMMISSION OF EUROPEAN COMMUNITIES . 2015

Caracterización molecular de células propagadoras de cáncer de pulmón como herramienta predictiva y para el diseño de terapias personalizadas

Investigador Principal: ROSA M FARRÀS RIVERA

INSTITUTO DE SALUD CARLOS III . 2016

Nuevos métodos para los retos emergentes en el análisis de datos de secuenciación masiva

Investigador Principal: SONIA TARAZONA CAMPOS

MINISTERIO DE ECON. Y COMPET. . 2015

Polímeros Terapéuticos diseñados para cruzar la Barrera Hematoencefálica para el tratamiento de desordenes neurodegenerativos-Explorando la Ruta Intranasal.

Investigador Principal: MARIA JESUS VICENT DOCON

MINISTERIO DE ECON. Y COMPET. . 2016

Combinatory treatment of Neural precursor cells and a new nanoconjugate of Fasudil for the clinical application in Acute Spinal Cord Injury

Investigador Principal: MARIA JESUS VICENT DOCON

FUNDACION LA MARATO DE TV3 . 2018

Estudio del papel de la GTPasa RAB11 en cáncer de próstata para su uso como biomarcador

Investigador Principal: ANA ARMIÑAN DE BENITO

CONSELLERIA DE EDUCACION . 2018

RTC-2017-6600-1 Desarrollo de una plataforma de terapia génica para enfermedades genéticas renales

Investigador Principal: MARIA JESUS VICENT DOCON

MINISTERIO DE CIENCIA, INNOVACION Y UNIVERSIDADES . 2018

Desarrollo de terapias tópicas basadas en sistemas de transporte polipeptídicos

Investigador Principal: MARIA JESUS VICENT DOCON

MINISTERIO DE CIENCIA, INNOVACION Y UNIVERSIDADES . 2018

Biomarcadores para oncología de precisión en cáncer de Pulmón, Colorrectal y Melanoma

Investigador Principal: CARMEN ESPINÓS ARMERO

AGENCIA VALENCIANA DE INNOVACIÓN . 2018

Compartir